BioSpace News Archive

Launch of two first-in-class medicines in 2023 marks start of exciting phase of growth for Ferring

Ferring published its 2023 Annual Report showing the company’s annual revenues were €2.2 billion, a decrease of -4% on the previous year at actual exchange rates, but an increase of +1% at constant exchange rates.

April 9, 2024
·
4 min read
Deals

Essential Pharma acquires Renaissance Pharma Ltd with its clinical stage immunotherapy for the treatment of high-risk neuroblastoma

Essential Pharma announces that it has completed the acquisition of the entire issued share capital of Renaissance Pharma Ltd.

April 9, 2024
·
5 min read
Biotech Beach

CLS Americas Announces 2nd Order of TRANBERG™ Focal Laser Ablation Accessories Placed by the National Institutes of Health Clinical Center

Clinical Laserthermia Systems Americas, Inc. announced it has received its second order from the National Institutes of Health Clinical Center for its TRANBERG™ Thermal Therapy System accessories.

April 9, 2024
·
3 min read
EFISHient Protein Announces Successful Development of Tilapia Cell Line

EFISHient Protein, a leading Israeli FoodTech company, proudly announces the successful completion of the Tilapia cell line development.

April 9, 2024
·
2 min read
Genetown

Seaport Therapeutics Launches with $100 Million Oversubscribed Series A Financing Round to Advance Novel Neuropsychiatric Medicines

Seaport Therapeutics, a clinical-stage biopharmaceutical company that is charting a proven path in neuropsychiatry, announced the closing of a $100 million oversubscribed Series A financing round.

April 9, 2024
·
7 min read
Immunovia successfully develops assays to measure targeted proteins for its next-generation pancreatic cancer test - moving forward towards model-development study

Immunovia, the diagnostics company with the mission to increase pancreatic cancer survival rates through early detection, announces that the company has successfully developed accurate and precise assays to measure targeted proteins for its next-generation test.

April 9, 2024
·
3 min read
Diakonos Oncology’s Unique Dendritic Cell Vaccine (DOC1021) Improves Survival Compared to Standard of Care in Phase 1 Trial for Glioblastoma

Diakonos Oncology Corp., a clinical-stage immuno-oncology company, announced today an interim analysis of the Phase 1 open label trial of DOC1021 showing substantially increased survival of glioblastoma multiforme

April 9, 2024
·
3 min read
Drug Development

BrainStorm Cell Therapeutics Announces Agreement with FDA on a Special Protocol Assessment (SPA) for Phase 3b Trial in ALS

BrainStorm Cell Therapeutics Inc. announced that it received written agreement from the U.S. Food and Drug Administration, under a Special Protocol Assessment, on the design for a Phase 3b trial of NurOwn® in amyotrophic lateral sclerosis.

April 9, 2024
·
8 min read
BioMidwest

Zomedica to Present at the Noble Capital Markets Virtual Healthcare Conference on April 17, 2024

Zomedica Corp. announced that its Chief Executive Officer, Larry Heaton, will present at the Noble Capital Markets’ Emerging Growth Virtual Healthcare Equity Conference on Wednesday, April 17, 9:30 a.m. - 10:00 a.m. ET, on Track 2.

April 9, 2024
·
2 min read
BioCapital

NeoImmuneTech’s NT-I7 in Combination with Chemotherapy Shows Efficacy in Colorectal Cancer at AACR Meeting

NeoImmuneTech, Inc. today presented a poster on a pre-clinical study that opens a new field of potential applications for NT-I7 (efineptakin alfa).

April 9, 2024
·
4 min read